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DasatiNib, HigH-Dose imatiNib aND NilotiNib iN CHiNese PatieNts WitH 
CHroNiC PHase of CHroNiC myeloiD leukemia WitH  
imatiNib-resistaNCe or -iNtoleraNCe: aN eCoNomiC evaluatioN
Wu B
Ren ji Hospital, affiliated with the School of Medicine, Shanghai Jiaotong University, Shanghai, 
China
Objectives: To evaluate the cost-effectiveness of dasatinib versus nilotinib and 
high-dose imatinib (600 or 800 mg) for people with chronic myeloid leukemia (CML) 
in chronic, accelerated and blast phase (CP, AP and BP), which are resistant or intoler-
ant to normal-dose imatinib, from the perspective of the Chinese healthcare sys-
tem. MethOds: A Markov cohort model was adapted to Chinese treatment practice. 
Clinical and utility data were taken mostly from the literature by a MEDLINE search. 
Costs were based on local charges. The primary output was reported in terms of 
incremental cost-effectiveness ratios (ICERs). Univariate and probabilistic sensitiv-
ity analyses were performed to examine the robustness of the model output. The 
impact of patient assistance program (PAP, buy three- month and get nine-month 
free) was assessed. Results: In chronic phase, the base case analysis showed the 
dominance of dasatinib versus nilotinib and imatinib 800 mg strategies because 
dasatinib gained more quality-adjusted life years (QALYs) with lower costs. For 
CML-CP patients, dasatinib is expected to provide more QALYs with more costs in 
comparison with imatinib 600 strategy, yielding an ICER of ¥369,767 /QALY. When 
PAP was available, the ICER of dasatinib versus 600 mg imatinib was ¥101,453, and 
nilotinib and 800 mg imatinib were dominated in patients with CP. When 3 times 
per Capita GDP of China (¥125,414 /QALY) according to WHO recommendations was 
used as the threshold and PAP was provided, dasatinib achieved about 90% probabili-
ties of cost-effectiveness in chronic phase. The uncertainties could be contributed 
to the costs of drugs. cOnclusiOns: The results indicate that PAP could notably 
improve the cost-effectiveness of dasatinib versus nilotinib and high-dose imatinib 
among imatinib-resistant or intolerant CML patients in China. Dasatinib is likely to 
be cost-saving versus nilotinib or imatinib 800 mg strategies in CML-CP patients.
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Cost-effeCtiveNess of iDelalisib Plus rituximab iN CHroNiC 
lymPHoCytiC leukaemia
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1PUBLIC HEALTH EXPERTISE, Paris, France, 2ICON Health Economics and Epidemiology, Oxford, 
UK, 3Gilead Sciences Europe Ltd, Uxbridge, UK, 4GILEAD, Boulogne, France
Objectives: Chronic Lymphocytic Leukaemia (CLL) is an indolent progressive 
hematologic disease. Current treatments for CLL are not curative and subjects 
become increasingly resistant to subsequent therapies. Patients relapsing after 
a disease-free period shorter than 2 years have an anticipated overall survival of 
45% at 3 years. Idelalisib + rituximab is improving overall and progression-free 
survival compared to rituximab + placebo in early (< 2 years) relapsed CLL patients. 
This trial was stopped early because of overwhelming efficacy. We estimated the 
cost-effectiveness of Idelalisib + rituximab in the French context. MethOds: A 
partitioned survival model was used to compare Idelalisib + rituximab to currently 
available treatments in France: alemtuzumab, bendamustine-rituximab and ibru-
tinib for CLL patients with early relapse and fludarabine-cyclophosphamide-ritux-
imab, bendamustine-rituximab and ibrutinib for CLL patients with late relapse. 
Because of the lack of an identifiable trial network and the presence of single 
arm trials, we used an innovative approach for comparing survivals. In essence, 
the modelling was based on fitting a general survival parametric function for all 
treatments, and then adjusting the scale parameters of the function to fit the 
observed survivals in each study (i.e.”common gamma approach”). Time horizon 
was 10 years. Utilities associated with different stages of disease were based on 
data from the literature. French direct medical costs were used. Outcomes and 
costs were discounted at 4%. Price for idelalisib was the price used in the early 
access program in France. Results: Idelalisib + rituximab was associated with 
incremental cost-effectiveness ratios of 30 480 € /QALY in early relapse and 31 
312 € /QALY in late relapse. Sensitivity analyses showed that the result was highly 
sensitive to the efficacy of idelalisib partly explained by the immaturity of the 
survival data coming from a clinical study with early termination. cOnclusiOns: 
Idelalisib is a cost-effective option for the treatment of early and late relapse CLL 
 patients.
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HealtH eCoNomiCs aND raDium-223 (xofigo®) iN tHe treatmeNt of 
metastatiC CastratioN-resistaNt Prostate CaNCer (mCrPC).  
a Case History aND a systematiC revieW of tHe literature oN  
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Objectives: Prostate cancer (PC) is the most common cancer in Western countries. 
Recent advances in the treatment of metastatic castration resistant prostate cancer 
(mCRPC) have caused significant pressure on health care budgets. We aimed to 
exemplify this dilemma presenting an example, radium-223 (Xofigo®), and review 
the literature on health technology assessments (HTA), cost-effectiveness analy-
sis (CEA) and guidelines. MethOds: A 74-year-old man diagnosed with mCRPC 
was referred to the Department of Radiology, University Hospital of North Norway 
(UNN) in October 2014 for radium-223 therapy. We faced the following dilemma: is 
radium-223 standard therapy? Is it cost-effective? Medline was searched employing 
the following search criteria: “radium-223”, “alpharadin”, “Xofigo” and “prostate”. 
Exclusion and inclusion criteria were applied. Guidelines and CEAs were focused. 
We also searched the websites of ASCO, ESMO and ISPOR. The web was searched, 
using Yahoo and Google search engines, for Health Technology Assessments 
(HTAs). Results: 181 publications were identified in the Medline database. Only 
health outcomes and cost-savings when used as prophylaxis of FN in patients with 
solid tumors or lymphoma receiving chemotherapy.
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Cost-effeCtiveNess aNalysis of obiNutuzumab/CHlorambuCil vs 
rituximab/CHlorambuCil iN treatmeNt of CHroNiC lymPHoCytiC 
leukemia
Yagudina R, Kulikov A, Babiy VV
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To conduct a cost-effectiveness assessment of obinutuzumab/chloram-
bucil (G-Clb) vs rituximab/chlorambucil (R-Clb) in treatment of chronic lymphocytic 
leukemia (1st line treatment) among elderly patients with coexisting conditions in 
the Russian Federation. MethOds: To conduct present study there was developed a 
special model (time horizon – 36 months). All necessary data was obtained from CLL 
11. Effectiveness analysis was based on the following criteria – number of life years. 
Cost analysis included only direct costs on the treatment of CLL (1st line: G-Clb or 
R-Clb, 2nd and 3rd lines – Bendamustin-Rituximab) and severe adverse events. Cost 
data was based on median prices for medicines and medical services in National 
healthcare system in the Russian Federation. Results: Total costs per patient in 
the group of G-Clb were 3217189 rubbles (€ 59688) and for R-Clb - 3102020 rubbles 
(€ 57552). The number of life years for G-Clb was 2,88 and for R-Clb - 2,75. Cost-
effectiveness ratio for G-Clb was 1116724 (€ 20719) and for R-Clb was 1129204 rubbles 
(€ 20950). cOnclusiOns: Due to the lower cost-effectiveness ratio, the use of G-Clb 
instead of R-Clb in treatment of CLL among elderly patients with coexisting conditions 
in the Russian Federation is more reasonable from a pharmacoeconomic point of view.
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Cost-effeCtiveNess aNalysis of Cetuximab aND PaNitumumab for 
first liNe treatmeNt of metastatiC ColoreCtal CaNCer (mCrC) iN Wt 
ras PatieNts iN sPaiN
Suarez J
Merck, Madrid, Spain
Objectives: The recent indication adjustment of anti-EGFR antibodies cetuximab 
and panitumumab according to RAS biomarker evidences the need to update their 
incremental cost-effectiveness ratios (ICER) as first line therapies in WT RAS mCRC 
patients. MethOds: Literature review about overall survival (OS) with both anti-
bodies in WT RAS mCRC patients. Analysis from the hospital pharmacy’s point of 
view of the cost of life year gained (LYG) based on the results of effectiveness in the 
published reviews for each therapy. The review of the specifications data sheets and 
clinical practice guidelines were used to establish the frequency of administration 
whereas dose regimen was calculated considering the standard values for weight 
as 70kg and body surface as 1.79m2. Results: CRYSTAL trial shows a difference 
of 8.2 months in OS for cetuximab +FOLFIRI vs FOLFIRI (28.4m vs 20.2m; HR: 0.69; 
p= 0.0024), while PRIME trial estimates a profit of 5.8m for panitumumab+FOLFOX 
vs FOLFOX (26.0m vs 20.2m; HR: 0.78; p= 0.04) and FIRE 3 study finds a difference of 
8.1m for cetuximab+FOLFIRI vs bevacizumab+FOLFIRI (33.1m vs 25.0m; HR: 0.697; 
p= 0.0059). The ICER for cetuximab+FOLFIRI vs FOLFIRI is estimated in 27,215€ /
LYG vs 35,367€ /LYG for panitumumab+FOLFOX vs FOLFOX and 5,162€ /LYG for 
cetuximab+FOLFIRI vs bevacizumab+FOLFIRI. During the execution of this analysis, 
the complete results of the CALGB-80405 clinical trial were not available and thus 
were not included in this evaluation. cOnclusiOns: Cetuximab is the biological 
therapy which optimizes the OS and minimizes the cost per LYG in first line treat-
ments for wt RAS patients, with a lower ratio than the usual 30,000 € /LYG threshold. 
These results are in line with the recent decisions of the National Cancer Drugs Fund 
about biological therapies in mCRC (NHS, January and March 2015).
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ColoreCtal CaNCer (mCrC) iN Colombia
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Objectives: To perform a cost-effectiveness analysis of Panitumumab+FOLFOX 
as first-line treatment in mCRC WT-RAS patients compared to 
Cetuximab+FOLFIRI. MethOds: A seven health stages Markov Model (progression-
free, metastasis resection, second-line progression, palliative care, no-progression 
after resection, progression after resection, and death) were evaluated in two-week 
transition cycles in a lifetime scenario. Since no head to head trials have been con-
ducted comparing Panitumumab and Cetuximab in first line treatment of WT RAS 
patients, an indirect comparison was performed to obtain the relative Progression-
free survival (PFS) and global survival (OS) between both epidermal growth fac-
tor receptor inhibitors (anti-EGFR). By linking PEAK and FIRE-3 trials (assuming 
that FOLFOX and FOLFIRI are equal) via a common evidence base (in this case 
Bevacizumab). Parametric survival modeling was used to extrapolate beyond the 
data collection period. The resource use and treatment patterns were obtained from 
three oncologists through a modified Delphi panel. Costs include testing for RAS 
mutation status; drug administration, chemotherapy, clinician visits, and diagnos-
tic tests; treating grade 3/4 toxicities; metastasis resection; second-line treatment; 
and palliative care. For all procedures Social Security cost (ISS+30) were applied; 
and SISMED prices for drugs. Clinical costs and benefits are discounted 5% per 
annum. Results: The mean discounted OS derived from the model was 45.3 and 
41.8 months with Panitumumab+FOLFOX6 and Cetuximab+FOLFIRI respectively; 
and a mean discounted PFS of 14.8 and 10.8 months. The total average cost with 
Panitumumab is USD$81,522.32 and USD$80,241.83 with Cetuximab. The longer pre-
dicted survival for a patient treated with Panitumumab result in a lower cost per life-
year (LY) (USD$21,613.42) compared to Cetuximab (USD$23,036.94). cOnclusiOns: 
Based on the adjusted PEAK-FIRE3 results, Panitumumab showed treatment out-
comes improvement vs Cetuximab for WT-RAS patients at a lower cost per life year.
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mography ranged from (2015US)$7,221-$39,251/QALY compared to no screening. 
Also for high-risk women, combined MRI and mammography were associated 
with ICERs from (2015US)$19,288/QALY to dominant compared to mammogra-
phy alone. These results include women of any age and mammography of any 
type. cOnclusiOns: Results suggest that annual mammography is mostly 
cost-effective when compared to no screening. According to a $100,000/QALY 
threshold, most of analyzed studies suggest that combined screening is cost-
effective in high-risk women compared to mammography alone, despite a wide 
cost-effectiveness ratios range. Notwithstanding the high level of heterogeneity 
among selected studies, this review provides a comprehensive overview of the 
cost-effectiveness of BCS and could serve in the realization of future economic 
evaluations.
PCN178
eCoNomiC evaluatioNs of glioblastoma
Lachaine J, Benmouhoub I, Mathurin K
University of Montreal, Montreal, QC, Canada
Objectives: Glioblastoma is a most aggressive primary brain tumor. Few eco-
nomic evaluations have been performed to evaluate treatments in glioblastoma. 
The objective of this literature review was to identify the characteristics of eco-
nomic evaluations in glioblastoma and the methods used to assess their economic 
impact. MethOds: A literature search was performed using MEDLINE and EMBASE 
electronic databases from January 2004 until February 2014 to identify economic 
evaluations of glioblastoma. Titles were initially screened for relevance. Then, 
abstracts of potentially relevant studies were reviewed. Finally, full-text articles were 
obtained for studies deemed relevant according to the abstract and were analyzed 
in details and relevant characteristics were extracted. Results: A total of 1,666 
potentially relevant studies were identified. After screening titles and abstracts, 105 
full-text articles were assessed according to the eligibility criteria and 14 studies 
were included. Cost-effectiveness and cost-utility analyzes were performed in 86% 
of studies. Thirty six percent of the economic evaluations used a Markov model 
and fourteen percent used a decision tree. The time horizon varied from 1 year to 
lifetime, with 57% of studies with a time horizon of more than 5 years. A large major-
ity of the economic evaluations adopted the perspective of the healthcare system 
(n= 12) and two studies reported societal perspective. The largest proportion of the 
studies compared temozolomide to several chemotherapy used in glioblastoma 
(57%), followed by bevacizumab (7%), carmustine wafer (7%). Among studies that 
reported a cost per QALY or a cost per LYG (9 studies). Among these, 29% have an 
ICER of CAD$50,000 or less, while 43% have an ICER of CAD$100,000/(QALY, LYG) 
or less. cOnclusiOns: Despite the high level of heterogeneity among selected 
studies, this review provides a comprehensive overview of the cost-effectiveness 
of several treatments in glioblastoma and could serve in the realization of future 
economic evaluations.
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fixeD CombiNatioN NetuPitaNt aND PaloNosetroN is a Cost-effeCtive 
iNterveNtioN for tHe PreveNtioN of CHemotHeraPy-iNDuCeD Nausea 
aND vomitiNg iN tHe uk
D’agostino P1, Cawston H2, Bourhis F2, Turini M1, Ruffo P1, Mcguire A3
1Helsinn Healthcare SA, Pazallo, Switzerland, 2MAPI, Nanterre, France, 3London School of 
Economics, London, UK
Objectives: The objective was to evaluate the cost-effectiveness of an oral fixed 
combination netupitant and palonosetron (NEPA) compared with aprepitant and 
palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced 
nausea and vomiting (CINV) in patients undergoing treatment with highly or mod-
erately emetogenic chemotherapy (HEC or MEC) in the UK. MethOds: A systematic 
literature review and meta-analysis were undertaken to compare NEPA with currently 
recommended anti-emetics. Relative effectiveness was estimated over the acute (day 
1) and overall treatment (day 1-5) phases, taking complete response (CR, no emesis no 
rescue medication) and complete protection (CP, CR plus no more than mild nausea) 
as primary efficacy outcomes. A three health-state Markov cohort model, including 
CP, CR and incomplete response (no CR) for HEC and MEC, was constructed. A five 
day time horizon and UK NHS perspective were adopted. Transition probabilities 
were obtained by combining the response rates of CP and CR from NEPA trials and 
odds ratios from the meta-analysis. Utilities of 0.90, 0.70 and 0.24 were defined for CP, 
CR and incomplete response, respectively. Costs included medications and manage-
ment of CINV-related events and were obtained from the British National Formulary 
and NHS Reference Costs. The expected budgetary impact of NEPA was also evalu-
ated. Results: In HEC patients, the NEPA strategy was more effective than APPA 
(quality-adjusted life days [QALDs] of 4.263 versus 4.053; incremental emesis- and 
CINV-free days of +0.354 and +0.237 respectively) and was less costly (£66 versus £124), 
resulting in NEPA being the dominant strategy. In MEC patients, NEPA was also domi-
nant, cumulating in an estimated 0.182 extra QALDs at an incremental cost of -£7.35 
compared with PA. Introducing NEPA is estimated to provide net 5-year cumulative 
cost savings of £13,981,628. cOnclusiOns: The results suggest NEPA is cost-effective 
for preventing CINV associated with HEC and MEC in the UK.
PCN180
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four studies included the word “cost”, three “economics” and none “budget” in head-
ing or abstract. None of the publications were thorough of cost analysis (cost-effec-
tiveness, cost-utility, cost-minimizing or cost-of-illness analysis). Six HTAs and eight 
national guidelines were identified. The cost per quality adjusted life year (QALY) 
was indicated € 80.000-€ 94,000. HTAs concluded reimbursement being not recom-
mendable or no ultimate statement could be made. One pointed towards a limited 
use with caution. cOnclusiOns: Guidelines were based on data from randomized 
clinical trials (RCTs). Health economics was not considered when guidelines were 
made. Most HTAs concluded this therapy not cost-effective or there was insufficient 
data for final conclusions. Licensing and reimbursement processes should be run 
simultaneously.
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eCoNomiC evaluatioN for fluvestraNt 500 mg im versus exemesteNe 
iN egyPtiaN PatieNts WitH metastatiC breast CaNCer
Amin M1, Abo Taleb AM2
1astrazeneca, cairo, Egypt, 2WHO, Cairo, Egypt
Objectives: The main objective behind conducting this study was to evaluate the 
cost-effectiveness of fluvestratnt 500 mg against, exemestene in the treatment of 
metastatic breast cancer, for the Egyptian patients, from the national fund perspec-
tive over a time horizon of 3 years. MethOds: Markov chain model was applied 
with three health states. Utility data were incorporated. Costs were that of the 
fund list. Results presented in of QALYs. One-dimensional sensitivity analyses were 
employed. Results: During the three-year time horizon the total cumulative QALY 
gained for fluvestrant 500 mg was 1.58 QALY The total cumulative QALY gained for 
exemestene was a 0.43 QALY. cOnclusiOns: The introduction of fluvestrant 500 
mg to the national fund - system was found to be cost saving based strictly from its 
perspective the model addresses both the health and economic implications of both 
drugs. The result of the study suggest that fluvestrant 500 and helping for taking the 
decision for resource allocation towards the cost saving treatment .
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Objectives: To evaluate the cost-effectiveness of adding bevacizumab to single-
agent chemotherapy for platinum-resistant recurrent ovarian cancer. MethOds: 
A decision-tree model was constructed to evaluate the cost-effectiveness of adding 
bevacizumab to standard treatment with single-agent chemotherapy (BEV + CT) as 
compared to treatment with single-agent chemotherapy alone. Transition probabili-
ties were based on findings from AURELIA, an international randomized phase III 
clinical trial and the first to evaluate the survival benefits of adding bevacizumab 
to chemotherapy for women with platinum-resistant disease. Quality-adjusted 
life-years (QALYs), progression-free survival (PFS), and costs were modeled over a 
horizon of fifteen months. Assuming a U.S. public payer perspective, incremental 
cost-effectiveness ratios (ICERs) were evaluated as the incremental cost per QALY 
gained and the incremental cost per progression-free life-year saved. To evaluate 
the robustness of our results, we performed deterministic and probabilistic sensi-
tivity analyses. Results: The ICERs associated with BEV + CT were $285,624 per 
QALY gained and $151,059 per progression-free life-year saved. Varying transition 
probabilities, costs, and utilities across the expected distribution of each parameter 
resulted in 7.2% of ICER estimates falling below the commonly accepted willingness 
to pay (WTP) threshold of $50,000/QALY gained; at a WTP threshold of $100,000/QALY 
gained, 22% of ICER estimates were cost-effective. One-way deterministic sensitivity 
analysis suggests that BEV + CT would become cost-effective at a WTP threshold of 
$50,000/QALY gained if the cost of treatment was reduced by 65%. cOnclusiOns: 
Despite gains in QALYS and PFS, the addition of bevacizumab to single-agent chemo-
therapy for the treatment of platinum-resistant recurrent ovarian cancer would not 
be considered cost effective at a willingness to pay threshold of $50,000/QALY gained 
or $100,000/QALY gained. On a per-patient basis, individual expected benefits, risks, 
and costs associated with treatment should be taken into consideration when pre-
scribing bevacizumab.
PCN177
literature revieW of eCoNomiC evaluatioNs of sCreeNiNg tests for 
breast CaNCer
Lachaine J, Lambert-Obry V, Lemay M. M
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Objectives: The objective of this literature review was to explore the existing 
evidences regarding cost-effectiveness of breast cancer screening (BCS) tests in 
average-risk women and in high-risk women. MethOds: A literature review was 
performed using the PICO method: Population consisted of women at average risk 
and at high risk for breast cancer; Intervention and Comparators were BCS tests, 
and Outcomes were incremental cost-effectiveness ratios (ICERs). The literature 
search was performed with the NHS EED filters using the electronic databases 
(MEDLINE, EMBASE and PubMed) from January 2005 until May 2015. Results: The 
literature review allowed retrieving 1,699 studies of which 39 fulfilled the eligibility 
criteria. Fourteen studies were cost-effectiveness analyses, twenty-one were cost-
utility analyses and four were both. Eighteen studies used a Markov model while 
seven studies used a decision tree. Time horizon varied from 5 years to lifetime. 
Main interventions compared were no screening, biennial mammography, annual 
mammography and annual mammography combined to MRI. For average-risk 
women, ICERs for biennial mammography varied between (2015US)$4,715-$21,747/
LYG and between (2015US)$7,548-$107,590/QALY compared to no screening, 
while ICERs for annual mammography ranged from (2015US)$24,124-$40,266/
LYG and (2015US)$69,217/QALY. For high-risk women, ICERs for annual mam-
